Shimizu Ayaka, Takenaka Kei, Ohata Shinya, Morimoto Kazuhide, Hashimoto Hiromi, Yamamoto Yuki, Itoh Toshio, Sugimoto Takeshi
Department of Hematology/Oncology, Kita-Harima Medical Center, Ono, Japan.
Division of Clinical Laboratory, Kita-Harima Medical Center, Ono, Japan.
Case Rep Oncol. 2021 Mar 1;14(1):217-223. doi: 10.1159/000512071. eCollection 2021 Jan-Apr.
This is a case report of a 60-year-old male patient with essential thrombocythemia (ET) that progressed to acute myeloid leukemia (AML) in approximately 9 years. His platelet count decreased approximately 8 years after ET treatment with hydroxyurea (HU) and aspirin. The dose of HU was reduced because of suspected myelosuppression due to HU; however, myelosuppression did not improve. Bone marrow examination revealed myelofibrosis; therefore, ruxolitinib was administered. Approximately 1 year later, his leukocyte and blast counts in the peripheral blood increased; thus, ET was judged to have progressed to AML-myelodysplasia-related change. Induction chemotherapy and consolidation therapy were initiated; however, the patient unfortunately failed to achieve complete remission. We then continued to administer salvage chemotherapy; however, his general condition worsened, and he died from cerebral hemorrhage. The karyotype at the onset of ET was 46,XY, which changed to 47,XY,del(7q),+8 at the time of AML diagnosis. In addition, genetic testing revealed mutation. His histopathological analysis showed subarachnoid and intraparenchymal hemorrhages and tumor cell infiltration into the cerebrum, brainstem, and cerebellum. In this case, deletion of the long arm of chromosome 7, additional abnormalities in chromosome 8, and -ITD mutation were confirmed as risk factors for having developed secondary AML for approximately 9 years and death from cerebral hemorrhage 1 year later.
这是一例60岁男性原发性血小板增多症(ET)患者的病例报告,该患者在约9年后进展为急性髓系白血病(AML)。在使用羟基脲(HU)和阿司匹林治疗ET约8年后,他的血小板计数下降。由于怀疑HU导致骨髓抑制,HU的剂量降低;然而,骨髓抑制并未改善。骨髓检查显示骨髓纤维化;因此,给予了鲁索替尼。大约1年后,他外周血中的白细胞和原始细胞计数增加;因此,ET被判定进展为AML-骨髓增生异常相关改变。开始进行诱导化疗和巩固化疗;然而,不幸的是患者未能达到完全缓解。然后我们继续给予挽救性化疗;然而,他的一般状况恶化,最终死于脑出血。ET发病时的核型为46,XY,在AML诊断时变为47,XY,del(7q),+8。此外,基因检测发现了 突变。他的组织病理学分析显示蛛网膜下腔和脑实质内出血以及肿瘤细胞浸润到大脑、脑干和小脑。在本病例中,7号染色体长臂缺失、8号染色体额外异常以及 -ITD突变被确认为约9年后发生继发性AML并在1年后死于脑出血的危险因素。